CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS

骨髓髓样细胞可以分为几类， 不同的自我更新能力携带形态 在成熟和不同的免疫表型方面的特征。 自我更新的潜力越大， 这些细胞。荧光激活细胞分选（FACS）已经被应用于临床。 用于培养早期髓样细胞群， 富含表型CD 34 + CD 38-Lin-Thy-1 +（lo）Rho（lo）。 这些细胞已被证明具有高增殖潜力。 一些AML细胞显示Thy-1+lo表型阴性。的 t（15; 17）AML亚群显示为CD 34 + CD 33-阴性。 细胞这一数据表明，一些预后良好的AML 亚群不渗透到早期骨髓室中， 而预后不良的亚组可能含有具有以下特征的细胞： 免疫表型CD 34 + CD 38-CD 33-Thy-1（lo）。我们将测试这个 假设通过使用高速FACS细胞分选来开发 来自AML患者的细胞群，其具有CD 34 + CD 38-T细胞亚群。 Lin-Thy+1（lo）Rho（lo）表型，然后通过FISH和PCR对其进行检测 寻找AML细胞的证据

Marrow myeloid cells can be separated into classes which exhibit different self-renewal capabilities carrying morphological features with respect to maturation and differing immunophenotype. The greater the self-renewal potential, the less frequent are these cells. Fluorescent activated cell sorting (FACS) has been used to develop populations of early myeloid cells which are enriched with the phenotype CD34+CD38-Lin-Thy-1 +(lo)Rho(lo). These cells have been shown to have high proliferative potential. Some AML cells show negativity for the Thy-1+lo phenotype. The t(15; 17) AML subset has been shown to be negative for CD34+CD33- cells. This data has suggested to some that the good prognosis AML subsets do not penetrate into the early myeloid compartment, whereas the poor prognostic subsets may contain cells with the immunophenotype CD34+CD38-CD33-Thy-1(lo). We will test this hypothesis by using high speed FACS cell sorting to develop populations of cells from AML patients which have the CD34+CD38- Lin-Thy+1(lo)Rho(lo) phenotype and then test this by FISH and PCR for evidence of AML cells.